Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Insmed Incorporated - Common Stock (NQ:INSM)

146.96 +0.64 (+0.44%)

Streaming Delayed Price Updated: 3:58 PM EST, Mar 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,460,518
Open	145.83
Bid (Size)	146.96 (500)
Ask (Size)	146.98 (100)
Prev. Close	146.32
Today's Range	143.76 - 148.31
52wk Range	60.40 - 212.75
Shares Outstanding	115,246,666
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗

Today 10:11 EST

PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates.

Via The Motley Fool

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗

March 02, 2026

This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach.

Via The Motley Fool

Performance

YTD	-17.0%	-17.0%
1 Month	-4.6%	-4.6%
3 Month	-30.5%	-30.5%
6 Month	+1.1%	+1.1%
1 Year	+92.6%	+92.6%

More News

Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗

March 02, 2026

Via The Motley Fool

Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗

February 23, 2026

Via The Motley Fool

This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗

February 23, 2026

Via The Motley Fool

Insmed (INSM) Q4 2025 Earnings Call Transcript ↗

February 19, 2026

Via The Motley Fool

Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗

February 17, 2026

Via The Motley Fool

Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗

February 17, 2026

Via The Motley Fool

Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗

February 17, 2026

Via The Motley Fool

Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗

February 14, 2026

Via The Motley Fool

Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million ↗

February 14, 2026

Via The Motley Fool

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM

January 20, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM

January 13, 2026

From Pomerantz LLP

Via GlobeNewswire

Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib ↗

January 06, 2026

Via The Motley Fool

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM

January 06, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM

December 30, 2025

From Pomerantz LLP

Via GlobeNewswire

INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm

December 29, 2025

From The Schall Law Firm

Via Business Wire

Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line ↗

December 28, 2025

Via The Motley Fool

Insmed Stock Plunges Nearly 20% After Hours As Sinus Drug Fails Mid-Stage Trial And Shows No Benefit ↗

December 17, 2025

Via Stocktwits

Wondering what's happening in today's after-hours session? ↗

December 17, 2025

Via Chartmill

Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗

December 03, 2025

Via The Motley Fool

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗

December 03, 2025

Via The Motley Fool

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗

December 03, 2025

Via The Motley Fool

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

December 03, 2025

Via MarketMinute

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

December 02, 2025

From BioMedWire

Via GlobeNewswire

Frequently Asked Questions

Is Insmed Incorporated - Common Stock publicly traded?

Yes, Insmed Incorporated - Common Stock is publicly traded.

What exchange does Insmed Incorporated - Common Stock trade on?

Insmed Incorporated - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Insmed Incorporated - Common Stock?

The ticker symbol for Insmed Incorporated - Common Stock is INSM on the Nasdaq Stock Market

What is the current price of Insmed Incorporated - Common Stock?

The current price of Insmed Incorporated - Common Stock is 146.96

When was Insmed Incorporated - Common Stock last traded?

The last trade of Insmed Incorporated - Common Stock was at 03/03/26 03:58 PM ET

What is the market capitalization of Insmed Incorporated - Common Stock?

The market capitalization of Insmed Incorporated - Common Stock is 16.94B

How many shares of Insmed Incorporated - Common Stock are outstanding?

Insmed Incorporated - Common Stock has 17B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.